The effect of low-intensity whole-body vibration with or without high-intensity resistance and impact training on risk factors for proximal femur fragility fracture in postmenopausal women with low bone mass: study protocol for the VIBMOR randomized controlled trial

• Published in: Current controlled trials in cardiovascular medicine Vol. 23; no. 1; p. 15
• Main Authors: Beck, Belinda, Rubin, Clinton, Harding, Amy, Paul, Sanjoy, Forwood, Mark
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.01.2022; BioMed Central; BMC
• Subjects: Australia; Bone Density; Care and treatment; Clinical medicine; Clinical trials; Demographic aspects; Diagnosis; Disease prevention; Drug therapy; Exercise; Falls; Female; Femoral Fractures; Femur; Fracture; Fractures; Hip joint; HiRIT; Humans; Injuries; Intervention; Muscle strength; Osteopenia; Osteoporosis; Osteoporosis, Postmenopausal - diagnosis; Osteoporosis, Postmenopausal - therapy; Physical fitness; Physical therapy; Postmenopausal women; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Research ethics; Risk Factors; Study Protocol; Testing; Therapeutics, Physiological; Vibration; Womens health; Australia; Osteoporosis; Fracture; Postmenopausal women; Exercise; Vibration; HiRIT
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-021-05911-4

The prevailing medical opinion is that medication is the primary (some might argue, only) effective intervention for osteoporosis. It is nevertheless recognized that osteoporosis medications are not universally effective, tolerated, or acceptable to patients. Mechanical loading, such as vibration and exercise, can also be osteogenic but the degree, relative efficacy, and combined effect is unknown. The purpose of the VIBMOR trial is to determine the efficacy of low-intensity whole-body vibration (LIV), bone-targeted, high-intensity resistance and impact training (HiRIT), or the combination of LIV and HiRIT on risk factors for hip fracture in postmenopausal women with osteopenia and osteoporosis. Postmenopausal women with low areal bone mineral density (aBMD) at the proximal femur and/or lumbar spine, with or without a history of fragility fracture, and either on or off osteoporosis medications will be recruited. Eligible participants will be randomly allocated to one of four trial arms for 9 months: LIV, HiRIT, LIV + HiRIT, or control (low-intensity, home-based exercise). Allocation will be block-randomized, stratified by use of osteoporosis medications. Testing will be performed at three time points: baseline (T0), post-intervention (T1; 9 months), and 1 year thereafter (T2; 21 months) to examine detraining effects. The primary outcome measure will be total hip aBMD determined by dual-energy X-ray absorptiometry (DXA). Secondary outcomes will include aBMD at other regions, anthropometrics, and other indices of bone strength, body composition, physical function, kyphosis, muscle strength and power, balance, falls, and intervention compliance. Exploratory outcomes include bone turnover markers, pelvic floor health, quality of life, physical activity enjoyment, adverse events, and fracture. An economic evaluation will also be conducted. No previous studies have compared the effect of LIV alone or in combination with bone-targeted HiRIT (with or without osteoporosis medications) on risk factors for hip fracture in postmenopausal women with low bone mass. Should either, both, or combined mechanical interventions be safe and efficacious, alternative therapeutic avenues will be available to individuals at elevated risk of fragility fracture who are unresponsive to or unwilling or unable to take osteoporosis medications. Australian New Zealand Clinical Trials Registry (www. anzctr.org.au ) (Trial number ANZCTR12615000848505, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id = 368962 ); date of registration 14/08/2015 (prospectively registered). Universal Trial Number: U1111-1172-3652.